These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 15501026)

  • 1. Increased plasma levels of soluble CD40, together with the decrease of TGF beta 1, as possible differential markers of Alzheimer disease.
    Mocali A; Cedrola S; Della Malva N; Bontempelli M; Mitidieri VA; Bavazzano A; Comolli R; Paoletti F; La Porta CA
    Exp Gerontol; 2004 Oct; 39(10):1555-61. PubMed ID: 15501026
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diagnostic utility of APOE, soluble CD40, CD40L, and Abeta1-40 levels in plasma in Alzheimer's disease.
    Ait-ghezala G; Abdullah L; Volmar CH; Paris D; Luis CA; Quadros A; Mouzon B; Mullan MA; Keegan AP; Parrish J; Crawford FC; Mathura VS; Mullan MJ
    Cytokine; 2008 Nov; 44(2):283-7. PubMed ID: 18835787
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum levels and genetic variation of TGF-beta1 are not associated with Alzheimer's disease.
    Rodríguez-Rodríguez E; Sánchez-Juan P; Mateo I; Llorca J; Infante J; García-Gorostiaga I; Berciano J; Combarros O
    Acta Neurol Scand; 2007 Dec; 116(6):409-12. PubMed ID: 17986101
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Elevated plasma levels of soluble CD40 in incipient Alzheimer's disease.
    Buchhave P; Janciauskiene S; Zetterberg H; Blennow K; Minthon L; Hansson O
    Neurosci Lett; 2009 Jan; 450(1):56-9. PubMed ID: 18996438
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased intrathecal TGF-beta1, but not IL-12, IFN-gamma and IL-10 levels in Alzheimer's disease patients.
    Rota E; Bellone G; Rocca P; Bergamasco B; Emanuelli G; Ferrero P
    Neurol Sci; 2006 Apr; 27(1):33-9. PubMed ID: 16688597
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vascular factors and markers of inflammation in offspring with a parental history of late-onset Alzheimer disease.
    van Exel E; Eikelenboom P; Comijs H; Frölich M; Smit JH; Stek ML; Scheltens P; Eefsting JE; Westendorp RG
    Arch Gen Psychiatry; 2009 Nov; 66(11):1263-70. PubMed ID: 19884614
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chitotriosidase and inflammatory mediator levels in Alzheimer's disease and cerebrovascular dementia.
    Di Rosa M; Dell'Ombra N; Zambito AM; Malaguarnera M; Nicoletti F; Malaguarnera L
    Eur J Neurosci; 2006 May; 23(10):2648-56. PubMed ID: 16817867
    [TBL] [Abstract][Full Text] [Related]  

  • 8. +10 T/C polymorphisms in the gene of transforming growth factor-beta1 are associated with neurodegeneration and its clinical evolution.
    Arosio B; Bergamaschini L; Galimberti L; La Porta C; Zanetti M; Calabresi C; Scarpini E; Annoni G; Vergani C
    Mech Ageing Dev; 2007 Oct; 128(10):553-7. PubMed ID: 17889927
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The CC genotype of transforming growth factor-β1 increases the risk of late-onset Alzheimer's disease and is associated with AD-related depression.
    Caraci F; Bosco P; Signorelli M; Spada RS; Cosentino FI; Toscano G; Bonforte C; Muratore S; Prestianni G; Panerai S; Giambirtone MC; Gulotta E; Romano C; Salluzzo MG; Nicoletti F; Copani A; Drago F; Aguglia E; Ferri R
    Eur Neuropsychopharmacol; 2012 Apr; 22(4):281-9. PubMed ID: 21924590
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CSF beta-amyloid 1-42 and tau in Tunisian patients with Alzheimer's disease: the effect of APOE epsilon4 allele.
    Smach MA; Charfeddine B; Lammouchi T; Harrabi I; Ben Othman L; Dridi H; Bennamou S; Limem K
    Neurosci Lett; 2008 Aug; 440(2):145-9. PubMed ID: 18555606
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cerebrospinal fluid beta-amyloid1-42 and tau in control subjects at risk for Alzheimer's disease: the effect of APOE epsilon4 allele.
    Sunderland T; Mirza N; Putnam KT; Linker G; Bhupali D; Durham R; Soares H; Kimmel L; Friedman D; Bergeson J; Csako G; Levy JA; Bartko JJ; Cohen RM
    Biol Psychiatry; 2004 Nov; 56(9):670-6. PubMed ID: 15522251
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasma and cerebrospinal fluid alpha1-antichymotrypsin levels in Alzheimer's disease: correlation with cognitive impairment.
    DeKosky ST; Ikonomovic MD; Wang X; Farlow M; Wisniewski S; Lopez OL; Becker JT; Saxton J; Klunk WE; Sweet R; Kaufer DI; Kamboh MI
    Ann Neurol; 2003 Jan; 53(1):81-90. PubMed ID: 12509851
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased cerebrospinal fluid levels of transforming growth factor-beta1 in Alzheimer's disease.
    Zetterberg H; Andreasen N; Blennow K
    Neurosci Lett; 2004 Sep; 367(2):194-6. PubMed ID: 15331151
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Growth factors decrease in subjects with mild to moderate Alzheimer's disease (AD): potential correction with dehydroepiandrosterone-sulphate (DHEAS).
    Luppi C; Fioravanti M; Bertolini B; Inguscio M; Grugnetti A; Guerriero F; Rovelli C; Cantoni F; Guagnano P; Marazzi E; Rolfo E; Ghianda D; Levante D; Guerrini C; Bonacasa R; Solerte SB
    Arch Gerontol Geriatr; 2009; 49 Suppl 1():173-84. PubMed ID: 19836631
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of omega-3 fatty acids on inflammatory markers in cerebrospinal fluid and plasma in Alzheimer's disease: the OmegAD study.
    Freund-Levi Y; Hjorth E; Lindberg C; Cederholm T; Faxen-Irving G; Vedin I; Palmblad J; Wahlund LO; Schultzberg M; Basun H; Eriksdotter Jönhagen M
    Dement Geriatr Cogn Disord; 2009; 27(5):481-90. PubMed ID: 19439966
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interleukin 6-174 G/C promoter gene polymorphism and sporadic Alzheimer's disease: geographic allele and genotype variations in Europe.
    Capurso C; Solfrizzi V; D'Introno A; Colacicco AM; Capurso SA; Capurso A; Panza F
    Exp Gerontol; 2004 Oct; 39(10):1567-73. PubMed ID: 15501028
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Altered plasma cytokine levels in Alzheimer's disease: correlation with the disease progression.
    Motta M; Imbesi R; Di Rosa M; Stivala F; Malaguarnera L
    Immunol Lett; 2007 Nov; 114(1):46-51. PubMed ID: 17949824
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of the Pro12Ala polymorphism of PPAR-gamma on age at onset and sRAGE levels in Alzheimer's disease.
    Yao L; Li K; Zhang L; Yao S; Piao Z; Song L
    Brain Res; 2009 Sep; 1291():133-9. PubMed ID: 19631630
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Apolipoprotein E genotype and age-related myelin breakdown in healthy individuals: implications for cognitive decline and dementia.
    Bartzokis G; Lu PH; Geschwind DH; Edwards N; Mintz J; Cummings JL
    Arch Gen Psychiatry; 2006 Jan; 63(1):63-72. PubMed ID: 16389198
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetic risk profiles for Alzheimer's disease: integration of APOE genotype and variants that up-regulate inflammation.
    Licastro F; Porcellini E; Caruso C; Lio D; Corder EH
    Neurobiol Aging; 2007 Nov; 28(11):1637-43. PubMed ID: 16930778
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.